See Table 1 for clinically significant drug interactions with dopamine.
Halogenated Anesthetics | |
Clinical Impact: | Concomitant use may increase cardiac autonomic irritability and can sensitize the myocardium to the action of dopamine which may lead to ventricular arrhythmias and hypertension. |
Intervention: | Monitor cardiac rhythm. |
Examples: | desflurane, enflurane, isoflurane, and sevoflurane. |
MAO Inhibitors | |
Clinical Impact: | Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine which may result in severe hypertension and cardiac arrhythmia. |
Intervention: | Reduce the recommended starting dosage to no greater than one-tenth (1/10) of the recommended dose in patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of Dopamine HCl in Dextrose Injection. |
Examples: | isocarboxazid, phenelzine, tranylcypromine, rasagiline, selegiline, linezolid. |
Tricyclic Antidepressants | |
Clinical Impact: | Concomitant use may potentiate the cardiovascular effects of dopamine (e.g., hypertension). |
Intervention: | Monitor blood pressure. |
Examples: | amitriptyline, desipramine, doxepin, imipramine, nortriptyline. |
Vasopressors | |
Clinical Impact: | Concomitant use may result in severe hypertension. |
Intervention: | Monitor blood pressure. |
Examples: | norepinephrine, epinephrine, oxytocin. |
See Table 1 for clinically significant drug interactions with dopamine.
Halogenated Anesthetics | |
Clinical Impact: | Concomitant use may increase cardiac autonomic irritability and can sensitize the myocardium to the action of dopamine which may lead to ventricular arrhythmias and hypertension. |
Intervention: | Monitor cardiac rhythm. |
Examples: | desflurane, enflurane, isoflurane, and sevoflurane. |
MAO Inhibitors | |
Clinical Impact: | Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine which may result in severe hypertension and cardiac arrhythmia. |
Intervention: | Reduce the recommended starting dosage to no greater than one-tenth (1/10) of the recommended dose in patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of Dopamine HCl in Dextrose Injection. |
Examples: | isocarboxazid, phenelzine, tranylcypromine, rasagiline, selegiline, linezolid. |
Tricyclic Antidepressants | |
Clinical Impact: | Concomitant use may potentiate the cardiovascular effects of dopamine (e.g., hypertension). |
Intervention: | Monitor blood pressure. |
Examples: | amitriptyline, desipramine, doxepin, imipramine, nortriptyline. |
Vasopressors | |
Clinical Impact: | Concomitant use may result in severe hypertension. |
Intervention: | Monitor blood pressure. |
Examples: | norepinephrine, epinephrine, oxytocin. |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.